TRISALUS LF SC CM A (TLSI)
Health Care · Clinical-stage biopharma and medical devices · NASDAQ
TriSalus is a clinical-stage biopharma and commercial medical device company developing immunotherapies and pressure-enabled drug delivery systems.
What TRISALUS LF SC CM A does
TriSalus Life Sciences is a commercial-stage medical device and Phase I clinical-stage pharmaceutical company. The company commercializes TriNav, a medical device product, and is developing nelitolimod, a pharmaceutical product candidate, along with other product candidates utilizing Pressure-Enabled Drug Delivery (PEDD) technology. The company operates with significant net losses and accumulated deficit, relying on capital raising and strategic partnerships to fund continued development and commercialization efforts.
Themes: ["immunotherapies","medical devices","drug delivery systems","clinical-stage development"]
Fundamentals
- Price$3.89 as of 2026-07-09 close
- Market cap$226M as of 2026-07-10
- 1-year return-28.8% as of 2026-07-09 close
- Net margin-60.9% as of 2026-07-10
- Gross margin+85.1% as of 2026-07-10
- ROE+12.0% as of 2026-07-10
- Debt / equity2.58 as of 2026-07-10
- Revenue growth (YoY)+39.6% as of 2026-07-10
- Revenue CAGR (3y)+53.9% SEC XBRL
- Beta0.42 as of 2026-07-10
Key risks (from latest filing)
["Limited operating history with accumulated deficit of $330.6 million as of December 31, 2025; significant ongoing losses with net losses of $39.2 million in 2025 and $30.0 million in 2024; uncertain path to profitability.","Dependence on raising additional capital through equity and debt financing; ability to access OrbiMed Credit Agreement and other funding sources is uncertain and may not be available on favorable terms.","Clinical development and regulatory approval risks for nelitolimod and other product candidates; preclinical testing and clinical trials are time-consuming, expensive, and uncertain with no guarantee of regulatory approval or commercial success."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.